# Epitranscriptomics in the Glioma Context: A Brief Overview

## TL;DR

This paper reviews how RNA modifications, known as epitranscriptomics, influence glioma development and progression, offering potential new therapeutic strategies.

## Contribution

The paper provides a comprehensive overview of RNA modifications in gliomas and their role in tumor progression and treatment.

## Key findings

- RNA modifications like N6-methyladenosine and pseudouridine are linked to glioma tumorigenesis.
- Dysregulation of epitranscriptomic proteins affects key pathways in glioma progression.
- Targeting RNA modifications presents new therapeutic opportunities for gliomas.

## Abstract

Epitranscriptomic modifications impact RNA stability and function, influencing key biological processes. While initially behind epigenetics, the field has advanced in the last decade, linking these modifications to development and diseases like cancer. High-grade gliomas, such as glioblastoma, remain challenging due to their aggressiveness and lack of effective treatments. Understanding the impact of epitranscriptomic alterations in gliomas may provide new insights into tumor progression and therapeutic strategies. This review provides an overview of RNA modifications in tRNAs, rRNAs, miRNAs, and mRNAs, exploring the role of the proteins involved in epitranscriptomics and their dysregulation in gliomas. We discuss how this imbalance affects pathways in glioma progression and highlight recent advancements in RNA modification-based therapeutics.

Epitranscriptomics, the study of chemical modifications in RNA, has emerged as a crucial field in cellular regulation, adding another layer to the established landscape of DNA- and histone-based epigenetics. A wide range of RNA modifications, including N6-methyladenosine, pseudouridine, and inosine, have been identified across nearly all RNA species, influencing essential processes such as transcription, splicing, RNA stability, and translation. In the context of brain tumors, particularly gliomas, specific epitranscriptomic signatures have been reported to play a role in tumorigenesis. Despite growing evidence, the biological implications of various RNA modifications remain poorly understood. This review offers an examination of the main RNA modifications, the interplay between modified and unmodified molecules, how they could contribute to glioma-like phenotypes, and the therapeutic impact of targeting these mechanisms.